Related Experiment Video
Updated: Aug 8, 2026
07:30
Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
Published on: November 21, 2012
Dopamine partial agonist reverses amphetamine withdrawal in rats
C Orsini1, G F Koob, L Pulvirenti
1Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Rd., La Jolla, CA 92037, USA.
Summary
Amphetamine withdrawal reduces motivation for rewards. Terguride, a dopamine partial agonist, reversed this effect in rats, suggesting its potential for treating acute amphetamine addiction withdrawal.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Research
Background:
- Amphetamine withdrawal is characterized by decreased motivation for natural rewards.
- This anhedonia is linked to reduced function in the mesolimbic dopamine system.
- Rats undergoing amphetamine withdrawal exhibit diminished responding for sucrose rewards on a progressive ratio schedule.
Purpose of the Study:
- To investigate the therapeutic potential of terguride in mitigating amphetamine withdrawal symptoms.
- To explore the role of dopamine partial agonists in restoring motivation during amphetamine withdrawal.
Main Methods:
- Rats were subjected to repeated amphetamine administration to induce withdrawal.
- Behavioral testing involved a progressive ratio schedule assessing responding for a sweet solution.
- Systemic administration of terguride (0.2 and 0.4 mg/kg) was performed twice daily during early withdrawal.
Main Results:
- Amphetamine withdrawal significantly reduced the rats' motivation to work for the sweet solution.
- Twice-daily administration of terguride effectively reversed the decrease in motivated responding.
- The effect was observed with both tested doses of terguride.
Conclusions:
- Dopamine partial agonists, like terguride, may offer a therapeutic strategy for acute amphetamine withdrawal.
- Agonistic actions of terguride under withdrawal conditions appear to restore reward-seeking behavior.
- This suggests a potential treatment avenue for the challenging early stages of amphetamine addiction recovery.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...